Q32 Bio (QTTB) Expected to Release Quarterly Earnings on Thursday

Q32 Bio (NASDAQ:QTTB) is anticipated to issue its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect the company to post earnings of ($0.36) per share for the quarter. Investors may review the information on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 7:00 AM ET.

Q32 Bio (NASDAQ:QTTB) last released its quarterly earnings data on Wednesday, November 4th. The company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.07. The business had revenue of $0.17 million for the quarter, compared to the consensus estimate of $0.17 million. On average, analysts expect Q32 Bio to post ($1.54) EPS for the current fiscal year and ($1.85) EPS for the next fiscal year.

Q32 Bio Stock Performance

Shares of Q32 Bio stock opened at $8.97 on Thursday. The firm’s 50-day simple moving average is $10.00 and its 200-day simple moving average is $9.30. Q32 Bio has a twelve month low of $1.90 and a twelve month high of $23.57. The firm has a market cap of $267.04 million, a P/E ratio of 4.23 and a beta of 0.45.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on QTTB shares. Morgan Stanley began coverage on shares of Q32 Bio in a research report on Monday, August 24th. They issued an “overweight” rating and a $34.00 price target for the company. Oppenheimer reiterated an “outperform” rating on shares of Q32 Bio in a research note on Thursday, October 1st. Mizuho upgraded Q32 Bio to a “strong-buy” rating in a research note on Monday, September 7th. Weiss Ratings raised Q32 Bio from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, August 21st. Finally, Leerink Partners initiated coverage on Q32 Bio in a research report on Monday, October 12th. They set an “outperform” rating and a $40.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $32.17.

Insider Activity at Q32 Bio

In other news, CEO Jodie Morrison sold 3,221 shares of the firm’s stock in a transaction on Tuesday, October 6th. The stock was sold at an average price of $8.32, for a total value of $26,798.72. Following the completion of the sale, the chief executive officer directly owned 340,038 shares in the company, valued at approximately $2,829,116.16. This trade represents a 0.94% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Lee Kalowski sold 3,972 shares of Q32 Bio stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $16.56, for a total value of $65,776.32. Following the completion of the transaction, the chief financial officer directly owned 138,471 shares of the company’s stock, valued at $2,293,079.76. This represents a 2.79% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 22,054 shares of company stock valued at $320,397 in the last three months. Corporate insiders own 34.46% of the company’s stock.

Q32 Bio Company Profile

Q32 Bio Inc (NASDAQ: QTTB) is a clinical-stage biotechnology company focused on developing biologic therapies for diseases associated with immune-system dysfunction. The company’s research programs are designed to restore immune balance rather than broadly suppress immune activity.

Q32 Bio’s lead product candidate is bempikibart, formerly known as ADX-914, a fully human monoclonal antibody that targets activin receptor type IIA (ActRIIA). The company has evaluated bempikibart in inflammatory and autoimmune conditions, including atopic dermatitis and alopecia areata.

The company also has pursued additional immunology programs, including therapies intended to address complement-mediated disease.